Pet CBD Market
Pet CBD Market Size and Share Forecast Outlook 2026 to 2036
Global Pet CBD Market Forecast and Outlook 2026 to 2036
The global pet CBD market is expected to reach USD 0.6 billion in 2026 and expand to USD 10.1 billion by 2036, growing at a 33.0% CAGR. Over the next decade, growth is being shaped less by broad retail expansion and more by the ability to scale trust under regulatory scrutiny. This is a market where demand is often triggered by condition intent, yet regulators treat disease mitigation claims as a drug boundary in animals. The FDA’s position on cannabis-derived products and enforcement actions in animal CBD clarify that product pages, marketing copy, and customer service scripts are commercial risk surfaces, not only legal artifacts.
Commercial winners are building operating models that look closer to consumer health than lifestyle supplements. This includes governance over claim language, batch-level quality documentation, and consistent potency and contaminant controls that reduce delisting risk on large platforms. FDA warning letters issued in 2025 to companies selling CBD products intended for animals illustrate the practical consequences of non-compliant positioning, including the agency treating promoted animal products as unapproved new animal drugs when claims cross disease boundaries.
Cross-country policy divergence amplifies the need for market-specific execution. The UK Veterinary Medicines Directorate states that CBD products for use in animals require a veterinary marketing authorisation to be sold or supplied in the UK and that no CBD-based products have been granted such authorisation. This creates a hard ceiling on fully compliant mass-market scaling in the UK and shifts strategy toward regulatory readiness rather than fast omnichannel rollout. In Canada, Health Canada has stated it is committed to exploring a regulatory pathway for veterinary drugs containing CBD that may be accessed without a prescription, signaling that compliant scale is expected to consolidate around formal frameworks rather than informal supplement positioning.
“The pet market is a dynamic sector that faced notable economic challenges and consumer shifts in the past year.”
Shannon Brown, Brand Manager for Packaged Facts Pet, March 7, 2024.
Quick Stats for the Pet CBD Market
- Expected Value of Pet CBD Market (2026): USD 0.6 billion
- Projected Value of Pet CBD Market (2036): USD 10.1 billion
- Growth Rate of the Pet CBD Market (2026 to 2036): 33.0% CAGR
- Leading Source Segment: Hemp (82.0%)
- Leading Indication Segment: Epilepsy (34.0%)
- Leading End User Channel: E-commerce Websites (46.0%)
- Key Countries in the Pet CBD Market: USA, UK, Germany, Canada, Australia
- Key Companies Profiled: Charlotte’s Web, CV Sciences, Elixinol, Medterra, Pet Releaf, HolistaPet, Endoca, Canopy Growth, Aurora Cannabis, Green Roads
Pet CBD Market Key Takeaways
| Metric | Value |
|---|---|
| Market Value (2026E) | USD 0.6 billion |
| Expected Value (2036F) | USD 10.1 billion |
| Forecast CAGR (2026 to 2036) | 33.0% |
Source: FMI’s proprietary forecasting model and primary research
Why is the Pet CBD Market Growing?
Pet CBD is growing because the category is being purchased as a problem-led wellness tool rather than a routine supplement, and because digital commerce makes education and replenishment scalable even when mainstream retail is constrained. Survey-based consumer openness reported in pet industry trade coverage indicates that interest extends beyond current users, supporting continued conversion potential when trust and compliance are managed.
Growth is also being reinforced by a market mechanics shift: claims discipline is forcing brands to compete on what they can document. In the United States, the FDA has issued warning letters tied to animal CBD products promoted with disease-relateing that the enforcement environment is active and that marketing language can directly trigger unapproved new animal drug treatment. This pushes companies to invest in content governance, batch substantiation, and controlled education that can survive platform and regulator scrutiny.
Channel mix reinforces this trajectory. E-commerce enables brands to standardize dosing guidance, publish batch documentation, manage reviews, and operate subscription replenishment models that reduce churn. Physical channels can still matter, but they demand stronger documentation and staff education, especially where veterinary-adjacent outlets are involved.
How is the Pet CBD Market Segmented?
The pet CBD market is segmented by source, indication, and end user channel. By source, the market includes hemp and marijuana, reflecting differences in supply chain traceability and perceived regulatory manageability. By indication, demand is clustered around epilepsy, sleep disorders, cancer, and bowel disorders, which shape urgency, repeat purchase behavior, and claim risk.
By end user channel, distribution spans e-commerce websites, pet shops, and veterinary hospital pharmacies, highlighting the tension between high-education digital selling and higher-credibility clinical-adjacent dispensing.
Why does Hemp Lead by Source in the Pet CBD Landscape?
Hemp leads with an 82.0% share because it supports scalable commercialization under tighter compliance postures. Hemp sourcing enables more standardized cannabinoid profiles and traceability narratives that are easier to operationalize across markets where claim boundaries already raise risk. This matters in channels that require documentation discipline and in jurisdictions where CBD animal products are under explicit regulatory scrutiny.
Why do E-commerce Websites Dominate by End User Channel in Pet CBD?
E-commerce websites account for 46.0% of sales because the purchase decision requires education, dosing confidence, and trust signaling that are difficult to deliver through shelf labels. Digital environments allow controlled language, structured FAQs, and batch documentation disclosure, which is commercially valuable when regulators actively challenge disease-positioned claims and when platforms want to reduce compliance exposure.
Which Dynamics Influence Growth of the Pet CBD Market?
Claims governance is becoming a core growth driver because it determines whether brands can scale without repeated enforcement resets. FDA actions illustrate that products promoted for animal disease-related uses can be treated as unapproved new animal drugs, creating disruption risk through forced revisions and channel instability.
Why do Authorization Requirements Act as a Structural Restraint in the UK?
In the UK, the Veterinary Medicines Directorate states that CBD products for animals require a veterinary marketing authorisation before they can be sold or supplied and that no CBD-based products have been granted such authorisation. This materially limits compliant mass-market distribution, raising the value of regulatory strategy and evidence planning over pure marketing scale.
How does a Formal Veterinary Drug Pathway Create New Market Opportunities in Canada?
Canada presents a clearer institutional direction because Health Canada has stated it is exploring a regulatory pathway for veterinary drugs containing CBD that may be accessed without a prescription. This signals future category maturation through formal frameworks and increases the strategic value of drug-style quality systems, stability discipline, and evidence readiness.
How are Enforcement Actions Tightening Channel Standards in the United States?
FDA warning letters and public updates on CBD enforcement increase the cost of non-compliant growth. Channel partners and platforms become more conservative when enforcement signals rise, which pushes brands toward conservative positioning, substantiation files, and documentation that can withstand scrutiny at the point of sale.
How will Pet CBD Demand evolve in Key Countries?
Growth trajectories across countries show clear divergence over the 2026 to 2036 period. Australia leads at 36.1% CAGR, reflecting strong consumer pull for pet wellness aids within a framework where classification and claims can trigger registration obligations. Canada follows at 35.0%, supported by a clearly stated regulatory exploration for non-prescription veterinary CBD drugs that signals a pathway to compliant scale.
UK, at 34.2%, shows rapid underlying demand but faces a hard compliance ceiling for authorized veterinary CBD products. Germany, at 33.6%, is shaped by veterinary medicine authorization logic and EU-style compliance expectations that reward documentation discipline. USA, at 31.5%, scales through advanced DTC execution while operating under active enforcement against unapproved animal drug claims.
| Country | CAGR (2026-2036) |
|---|---|
| USA | 31.5% |
| UK | 34.2% |
| Germany | 33.6% |
| Canada | 35.0% |
| Australia | 36.1% |
Source: Future Market Insights analysis, supported by a proprietary forecasting model and primary research
What is shaping pet CBD demand and commercial viability in the United States?
The pet CBD market in the United States is set to advance at a 31.5% CAGR. A large addressable base of pet owners, strong digital commerce infrastructure, and high willingness to pay for functional pet wellness products supports growth. The binding commercial constraint is enforcement risk tied to therapeutic positioning.
The FDA’s warning letter to Holista, LLC doing business as HolistaPet is a documented example where the agency reviewed online promotion and treated CBD animal products positioned for disease-related uses as unapproved new animal drugs. This creates repeatable operational consequences: product pages, ad copy, and customer support become compliance-controlled assets, and failure triggers forced revision cycles that interrupt acquisition funnels and channel continuity.
How does the United Kingdom’s veterinary medicines framework determine what can scale?
The UK is tracking a 34.2% CAGR, yet compliant scaling is structurally constrained by authorization rules. The VMD states that CBD products for animals require a veterinary marketing authorisation before being sold or supplied in the UK and that no CBD-based products have been granted such authorisation.
This drives behavior toward limited, high-friction channels and raises the value of evidence planning and regulatory strategy. VMD public guidance also states CBD products are not authorised for veterinary use, reinforcing that mainstream compliant expansion is not a distribution problem alone.
What evidence-linked constraints define Germany’s Adoption Curve and Route to Market?
Germany is expected to expand at a 33.6% CAGR, supported by strong pet care expenditure and demand for functional wellness. The gating factor is that veterinary medici to be marketed generally require official approval, which shapes how any product positioned with therapeutic intent can scale.
This pushes competitive execution toward conservative wellness framing, documentation readiness, and channel strategies that can sustain compliant education. In practice, products that imply treatment outcomes face a structural legitimacy barrier without authorization pathways, which compresses the compliant mass-market opportunity and raises the importance of claim governance and substantiation discipline.
Why does Canada present a Clearer Institutional Pathway Signal than Peer Markets?
Canada is projected to grow at a 35.0% CAGR and stands out because Health Canada has explicitly stated it is committed to exploring a regulatory pathway for veterinary drugs containing CBD that may be accessed without a prescription. This signals a direction of travel toward formal frameworks, not relaxed oversight.
Companies positioned to win are those building drug-style readiness, including quality systems, product consistency, and evidence strategies aligned to veterinary drug expectations. This pathway signal changes investment behavior by rewarding readiness for regulated scale rather than short-term demand capture alone.
How does Australia’s classification and registration logic shape competitive strategy?
Australia is expected to advance at a 36.1% CAGR. Demand is strong, but classification and claim framing determine whether products become subject to higher regulatory burdens. APVMA guidance indicates that cannabis-containing animal or pet food products must be registered if they meet the definition of a veterinary chemical product and that classification depends on the attributes, properties, and claims of the specific product.
This makes claim language a commercial risk lever. Products positioned with therapeutic implication raise the probability of registration exposure and enforcement risk, which pushes scaling brands toward conservative positioning, strict label governance, and documentation that supports channel confidence.
What is the Competition Outlook for Pet CBD?
The global pet CBD market in 2026 is shaped by enforcement sensitivity, authorization ceilings, and platform risk controls that directly influence portfolio design and channel strategy. Competitive positioning is defined by the ability to sustain compliant growth, not by aggressive indication marketing. FDA enforcement actions in animal CBD illustrate how quickly non-compliant claims can trigger disruption, making claims governance, batch documentation, and controlled education central to maintaining continuity in acquisition funnels.
Competitive advantage increasingly concentrates in companies that can industrialize quality and substantiation, including consistent potency disclosure, contaminant controls, and conservative benefit framing that avoids disease mitigation language. Channel control is equally decisive. E-commerce is structurally advantaged because it allows precise language control and documentation disclosure, while pet specialty and veterinary-adjacent outlets reward brands that can meet higher documentation and staff education thresholds.
Key Players Profiled
- Charlotte’s Web
- CV Sciences
- ElixinolMedterra
- Pet Releaf
- HolistaPet
- Endoca
- Canopy Growth
- Aurora Cannabis
- Green Roads
Market Definition
The pet CBD market represents revenue generated from commercially sold cannabidiol products intended for companion animals, including oils, tinctures, chews, treats, capsules, and topical formats positioned for animal wellness. As operationally defined in this analysis, the market measures products marketed for pet use and sold through digital channels, specialty pet retail, and veterinary-adjacent outlets where permitted, expressed in USD billion.
The market includes hemp-derived and marijuana-derived sourcing classifications and is analyzed by indication clusters including epilepsy, sleep disorders, cancer, and bowel disorders. The market excludes human CBD products not positioned for animal use, veterinary prescription pharmaceuticals not marketed as CBD wellness products, and revenues from cannabis cultivation that are not directly monetized through pet CBD product sales.
Scope of Report
| Items | Values |
|---|---|
| Quantitative Units (2026) | USD 0.6 billion |
| Source | Hemp, Marijuana |
| Indication | Epilepsy, Sleep Disorders, Cancer, Bowel Disorders |
| End User | E-commerce Websites, Pet Shops, Veterinary Hospital Pharmacies |
| Regions Covered | North America, Western Europe, Asia Pacific |
| Countries Covered | United States, United Kingdom, Germany, Canada, Australia |
| Key Companies Profiled | Charlotte’s Web, CV Sciences, Elixinol, Medterra, Pet Releaf, HolistaPet, Endoca, Canopy Growth, Aurora Cannabis, Green Roads |
| Additional Attributes | Dollar sales by source, indication, and end user channel, country-level growth divergence, enforcement-led claim governance, authorization ceilings in veterinary markets, pathway development for non-prescription veterinary CBD drugs, platform and retailer documentation thresholds, quality and traceability requirements |
Pet CBD Market by Key Segments
By Source:
- Hemp
- Marijuana
By Indication:
- Epilepsy
- Sleep Disorders
- Cancer
- Bowel Disorders
By End User:
- E-commerce Websites
- Pet Shops
- Veterinary Hospital Pharmacies
By Region:
- North America
- Latin America
- Western Europe
- Eastern Europe
- East Asia
- South Asia & Pacific
- Middle East & Africa
Bibliography
- USA Food and Drug Administration. (2025). Holista, LLC dba HolistaPet warning letter 699082.
- USA Food and Drug Administration. (2022). FDA warns companies for illegally selling CBD products intended for use in food-producing animals.
- UK Veterinary Medicines Directorate. (2018). VMD statement on veterinary medicinal products containing cannabidiol.
- Health Canada. (2025). Veterinary drugs containing cannabidiol for animal use.
- Health Canada. (2025). Overview: Towards a pathway for health products containing cannabidiol.
- Petfood Industry. (2024). Webinar: US pet market outlook for 2024.
Frequently Asked Questions
How big is the global pet CBD market?
The global pet CBD market is valued at USD 0.6 billion in 2026.
What is the growth outlook for the pet CBD market over the next 10 years?
The market is projected to grow at a 33.0% CAGR, reaching a valuation of USD 10.1 billion by 2036.
Which segments drive demand in this market?
Demand is structured by source, indication, and end user channel, with hemp holding 82.0% share, epilepsy representing 34.0% of indication-led demand, and e-commerce websites capturing 46.0% of sales.
What are the main risks and constraints affecting this market?
The primary constraints are authorization ceilings and enforcement against unapproved animal drug claims, illustrated by FDA warning letters and the UK requirement for veterinary marketing authorisation for animal CBD products.
How does market behavior differ by country?
Country outcomes differ based on regulatory pathway clarity, authorization rules, and classification triggers that are tied to claims and product positioning, with Canada signaling pathway development for non-prescription veterinary CBD drugs and the UK maintaining an authorization ceiling for CBD veterinary products.
Table of Content
- Executive Summary
- Global Market Outlook
- Demand to side Trends
- Supply to side Trends
- Technology Roadmap Analysis
- Analysis and Recommendations
- Market Overview
- Market Coverage / Taxonomy
- Market Definition / Scope / Limitations
- Research Methodology
- Chapter Orientation
- Analytical Lens and Working Hypotheses
- Market Structure, Signals, and Trend Drivers
- Benchmarking and Cross-market Comparability
- Market Sizing, Forecasting, and Opportunity Mapping
- Research Design and Evidence Framework
- Desk Research Programme (Secondary Evidence)
- Company Annual and Sustainability Reports
- Peer-reviewed Journals and Academic Literature
- Corporate Websites, Product Literature, and Technical Notes
- Earnings Decks and Investor Briefings
- Statutory Filings and Regulatory Disclosures
- Technical White Papers and Standards Notes
- Trade Journals, Industry Magazines, and Analyst Briefs
- Conference Proceedings, Webinars, and Seminar Materials
- Government Statistics Portals and Public Data Releases
- Press Releases and Reputable Media Coverage
- Specialist Newsletters and Curated Briefings
- Sector Databases and Reference Repositories
- FMI Internal Proprietary Databases and Historical Market Datasets
- Subscription Datasets and Paid Sources
- Social Channels, Communities, and Digital Listening Inputs
- Additional Desk Sources
- Expert Input and Fieldwork (Primary Evidence)
- Primary Modes
- Qualitative Interviews and Expert Elicitation
- Quantitative Surveys and Structured Data Capture
- Blended Approach
- Why Primary Evidence is Used
- Field Techniques
- Interviews
- Surveys
- Focus Groups
- Observational and In-context Research
- Social and Community Interactions
- Stakeholder Universe Engaged
- C-suite Leaders
- Board Members
- Presidents and Vice Presidents
- R&D and Innovation Heads
- Technical Specialists
- Domain Subject-matter Experts
- Scientists
- Physicians and Other Healthcare Professionals
- Governance, Ethics, and Data Stewardship
- Research Ethics
- Data Integrity and Handling
- Primary Modes
- Tooling, Models, and Reference Databases
- Desk Research Programme (Secondary Evidence)
- Data Engineering and Model Build
- Data Acquisition and Ingestion
- Cleaning, Normalisation, and Verification
- Synthesis, Triangulation, and Analysis
- Quality Assurance and Audit Trail
- Market Background
- Market Dynamics
- Drivers
- Restraints
- Opportunity
- Trends
- Scenario Forecast
- Demand in Optimistic Scenario
- Demand in Likely Scenario
- Demand in Conservative Scenario
- Opportunity Map Analysis
- Product Life Cycle Analysis
- Supply Chain Analysis
- Investment Feasibility Matrix
- Value Chain Analysis
- PESTLE and Porter’s Analysis
- Regulatory Landscape
- Regional Parent Market Outlook
- Production and Consumption Statistics
- Import and Export Statistics
- Market Dynamics
- Global Market Analysis 2021 to 2025 and Forecast, 2026 to 2036
- Historical Market Size Value (USD Million) Analysis, 2021 to 2025
- Current and Future Market Size Value (USD Million) Projections, 2026 to 2036
- Y to o to Y Growth Trend Analysis
- Absolute $ Opportunity Analysis
- Global Market Pricing Analysis 2021 to 2025 and Forecast 2026 to 2036
- Global Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By Source
- Introduction / Key Findings
- Historical Market Size Value (USD Million) Analysis By Source , 2021 to 2025
- Current and Future Market Size Value (USD Million) Analysis and Forecast By Source , 2026 to 2036
- Hemp
- Marijuana
- Hemp
- Y to o to Y Growth Trend Analysis By Source , 2021 to 2025
- Absolute $ Opportunity Analysis By Source , 2026 to 2036
- Global Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By Indication
- Introduction / Key Findings
- Historical Market Size Value (USD Million) Analysis By Indication, 2021 to 2025
- Current and Future Market Size Value (USD Million) Analysis and Forecast By Indication, 2026 to 2036
- Epilepsy
- Sleep Disorders
- Cancer
- Bowel Disorders
- Epilepsy
- Y to o to Y Growth Trend Analysis By Indication, 2021 to 2025
- Absolute $ Opportunity Analysis By Indication, 2026 to 2036
- Global Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By End User
- Introduction / Key Findings
- Historical Market Size Value (USD Million) Analysis By End User, 2021 to 2025
- Current and Future Market Size Value (USD Million) Analysis and Forecast By End User, 2026 to 2036
- E-commerce Websites
- Pet Shops
- Veterinary Hospital Pharmacies
- E-commerce Websites
- Y to o to Y Growth Trend Analysis By End User, 2021 to 2025
- Absolute $ Opportunity Analysis By End User, 2026 to 2036
- Global Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By Region
- Introduction
- Historical Market Size Value (USD Million) Analysis By Region, 2021 to 2025
- Current Market Size Value (USD Million) Analysis and Forecast By Region, 2026 to 2036
- North America
- Latin America
- Western Europe
- Eastern Europe
- East Asia
- South Asia and Pacific
- Middle East & Africa
- Market Attractiveness Analysis By Region
- North America Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By Country
- Historical Market Size Value (USD Million) Trend Analysis By Market Taxonomy, 2021 to 2025
- Market Size Value (USD Million) Forecast By Market Taxonomy, 2026 to 2036
- By Country
- USA
- Canada
- Mexico
- By Source
- By Indication
- By End User
- By Country
- Market Attractiveness Analysis
- By Country
- By Source
- By Indication
- By End User
- Key Takeaways
- Latin America Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By Country
- Historical Market Size Value (USD Million) Trend Analysis By Market Taxonomy, 2021 to 2025
- Market Size Value (USD Million) Forecast By Market Taxonomy, 2026 to 2036
- By Country
- Brazil
- Chile
- Rest of Latin America
- By Source
- By Indication
- By End User
- By Country
- Market Attractiveness Analysis
- By Country
- By Source
- By Indication
- By End User
- Key Takeaways
- Western Europe Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By Country
- Historical Market Size Value (USD Million) Trend Analysis By Market Taxonomy, 2021 to 2025
- Market Size Value (USD Million) Forecast By Market Taxonomy, 2026 to 2036
- By Country
- Germany
- UK
- Italy
- Spain
- France
- Nordic
- BENELUX
- Rest of Western Europe
- By Source
- By Indication
- By End User
- By Country
- Market Attractiveness Analysis
- By Country
- By Source
- By Indication
- By End User
- Key Takeaways
- Eastern Europe Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By Country
- Historical Market Size Value (USD Million) Trend Analysis By Market Taxonomy, 2021 to 2025
- Market Size Value (USD Million) Forecast By Market Taxonomy, 2026 to 2036
- By Country
- Russia
- Poland
- Hungary
- Balkan & Baltic
- Rest of Eastern Europe
- By Source
- By Indication
- By End User
- By Country
- Market Attractiveness Analysis
- By Country
- By Source
- By Indication
- By End User
- Key Takeaways
- East Asia Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By Country
- Historical Market Size Value (USD Million) Trend Analysis By Market Taxonomy, 2021 to 2025
- Market Size Value (USD Million) Forecast By Market Taxonomy, 2026 to 2036
- By Country
- China
- Japan
- South Korea
- By Source
- By Indication
- By End User
- By Country
- Market Attractiveness Analysis
- By Country
- By Source
- By Indication
- By End User
- Key Takeaways
- South Asia and Pacific Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By Country
- Historical Market Size Value (USD Million) Trend Analysis By Market Taxonomy, 2021 to 2025
- Market Size Value (USD Million) Forecast By Market Taxonomy, 2026 to 2036
- By Country
- India
- ASEAN
- Australia & New Zealand
- Rest of South Asia and Pacific
- By Source
- By Indication
- By End User
- By Country
- Market Attractiveness Analysis
- By Country
- By Source
- By Indication
- By End User
- Key Takeaways
- Middle East & Africa Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By Country
- Historical Market Size Value (USD Million) Trend Analysis By Market Taxonomy, 2021 to 2025
- Market Size Value (USD Million) Forecast By Market Taxonomy, 2026 to 2036
- By Country
- Kingdom of Saudi Arabia
- Other GCC Countries
- Turkiye
- South Africa
- Other African Union
- Rest of Middle East & Africa
- By Source
- By Indication
- By End User
- By Country
- Market Attractiveness Analysis
- By Country
- By Source
- By Indication
- By End User
- Key Takeaways
- Key Countries Market Analysis
- USA
- Pricing Analysis
- Market Share Analysis, 2025
- By Source
- By Indication
- By End User
- Canada
- Pricing Analysis
- Market Share Analysis, 2025
- By Source
- By Indication
- By End User
- Mexico
- Pricing Analysis
- Market Share Analysis, 2025
- By Source
- By Indication
- By End User
- Brazil
- Pricing Analysis
- Market Share Analysis, 2025
- By Source
- By Indication
- By End User
- Chile
- Pricing Analysis
- Market Share Analysis, 2025
- By Source
- By Indication
- By End User
- Germany
- Pricing Analysis
- Market Share Analysis, 2025
- By Source
- By Indication
- By End User
- UK
- Pricing Analysis
- Market Share Analysis, 2025
- By Source
- By Indication
- By End User
- Italy
- Pricing Analysis
- Market Share Analysis, 2025
- By Source
- By Indication
- By End User
- Spain
- Pricing Analysis
- Market Share Analysis, 2025
- By Source
- By Indication
- By End User
- France
- Pricing Analysis
- Market Share Analysis, 2025
- By Source
- By Indication
- By End User
- India
- Pricing Analysis
- Market Share Analysis, 2025
- By Source
- By Indication
- By End User
- ASEAN
- Pricing Analysis
- Market Share Analysis, 2025
- By Source
- By Indication
- By End User
- Australia & New Zealand
- Pricing Analysis
- Market Share Analysis, 2025
- By Source
- By Indication
- By End User
- China
- Pricing Analysis
- Market Share Analysis, 2025
- By Source
- By Indication
- By End User
- Japan
- Pricing Analysis
- Market Share Analysis, 2025
- By Source
- By Indication
- By End User
- South Korea
- Pricing Analysis
- Market Share Analysis, 2025
- By Source
- By Indication
- By End User
- Russia
- Pricing Analysis
- Market Share Analysis, 2025
- By Source
- By Indication
- By End User
- Poland
- Pricing Analysis
- Market Share Analysis, 2025
- By Source
- By Indication
- By End User
- Hungary
- Pricing Analysis
- Market Share Analysis, 2025
- By Source
- By Indication
- By End User
- Kingdom of Saudi Arabia
- Pricing Analysis
- Market Share Analysis, 2025
- By Source
- By Indication
- By End User
- Turkiye
- Pricing Analysis
- Market Share Analysis, 2025
- By Source
- By Indication
- By End User
- South Africa
- Pricing Analysis
- Market Share Analysis, 2025
- By Source
- By Indication
- By End User
- USA
- Market Structure Analysis
- Competition Dashboard
- Competition Benchmarking
- Market Share Analysis of Top Players
- By Regional
- By Source
- By Indication
- By End User
- Competition Analysis
- Competition Deep Dive
- Charlotte’s Web
- Overview
- Product Portfolio
- Profitability by Market Segments (Product/Age /Sales Channel/Region)
- Sales Footprint
- Strategy Overview
- Marketing Strategy
- Product Strategy
- Channel Strategy
- CV Sciences
- Elixinol
- Medterra
- Pet Releaf
- HolistaPet
- Endoca
- Canopy Growth
- Aurora Cannabis
- Green Roads
- Charlotte’s Web
- Competition Deep Dive
- Assumptions & Acronyms Used
List of Tables
- Table 1: Global Market Value (USD Million) Forecast by Region, 2021 to 2036
- Table 2: Global Market Value (USD Million) Forecast by Source , 2021 to 2036
- Table 3: Global Market Value (USD Million) Forecast by Indication, 2021 to 2036
- Table 4: Global Market Value (USD Million) Forecast by End User, 2021 to 2036
- Table 5: North America Market Value (USD Million) Forecast by Country, 2021 to 2036
- Table 6: North America Market Value (USD Million) Forecast by Source , 2021 to 2036
- Table 7: North America Market Value (USD Million) Forecast by Indication, 2021 to 2036
- Table 8: North America Market Value (USD Million) Forecast by End User, 2021 to 2036
- Table 9: Latin America Market Value (USD Million) Forecast by Country, 2021 to 2036
- Table 10: Latin America Market Value (USD Million) Forecast by Source , 2021 to 2036
- Table 11: Latin America Market Value (USD Million) Forecast by Indication, 2021 to 2036
- Table 12: Latin America Market Value (USD Million) Forecast by End User, 2021 to 2036
- Table 13: Western Europe Market Value (USD Million) Forecast by Country, 2021 to 2036
- Table 14: Western Europe Market Value (USD Million) Forecast by Source , 2021 to 2036
- Table 15: Western Europe Market Value (USD Million) Forecast by Indication, 2021 to 2036
- Table 16: Western Europe Market Value (USD Million) Forecast by End User, 2021 to 2036
- Table 17: Eastern Europe Market Value (USD Million) Forecast by Country, 2021 to 2036
- Table 18: Eastern Europe Market Value (USD Million) Forecast by Source , 2021 to 2036
- Table 19: Eastern Europe Market Value (USD Million) Forecast by Indication, 2021 to 2036
- Table 20: Eastern Europe Market Value (USD Million) Forecast by End User, 2021 to 2036
- Table 21: East Asia Market Value (USD Million) Forecast by Country, 2021 to 2036
- Table 22: East Asia Market Value (USD Million) Forecast by Source , 2021 to 2036
- Table 23: East Asia Market Value (USD Million) Forecast by Indication, 2021 to 2036
- Table 24: East Asia Market Value (USD Million) Forecast by End User, 2021 to 2036
- Table 25: South Asia and Pacific Market Value (USD Million) Forecast by Country, 2021 to 2036
- Table 26: South Asia and Pacific Market Value (USD Million) Forecast by Source , 2021 to 2036
- Table 27: South Asia and Pacific Market Value (USD Million) Forecast by Indication, 2021 to 2036
- Table 28: South Asia and Pacific Market Value (USD Million) Forecast by End User, 2021 to 2036
- Table 29: Middle East & Africa Market Value (USD Million) Forecast by Country, 2021 to 2036
- Table 30: Middle East & Africa Market Value (USD Million) Forecast by Source , 2021 to 2036
- Table 31: Middle East & Africa Market Value (USD Million) Forecast by Indication, 2021 to 2036
- Table 32: Middle East & Africa Market Value (USD Million) Forecast by End User, 2021 to 2036
List of Figures
- Figure 1: Global Market Pricing Analysis
- Figure 2: Global Market Value (USD Million) Forecast 2021-2036
- Figure 3: Global Market Value Share and BPS Analysis by Source , 2026 and 2036
- Figure 4: Global Market Y-o-Y Growth Comparison by Source , 2026-2036
- Figure 5: Global Market Attractiveness Analysis by Source
- Figure 6: Global Market Value Share and BPS Analysis by Indication, 2026 and 2036
- Figure 7: Global Market Y-o-Y Growth Comparison by Indication, 2026-2036
- Figure 8: Global Market Attractiveness Analysis by Indication
- Figure 9: Global Market Value Share and BPS Analysis by End User, 2026 and 2036
- Figure 10: Global Market Y-o-Y Growth Comparison by End User, 2026-2036
- Figure 11: Global Market Attractiveness Analysis by End User
- Figure 12: Global Market Value (USD Million) Share and BPS Analysis by Region, 2026 and 2036
- Figure 13: Global Market Y-o-Y Growth Comparison by Region, 2026-2036
- Figure 14: Global Market Attractiveness Analysis by Region
- Figure 15: North America Market Incremental Dollar Opportunity, 2026-2036
- Figure 16: Latin America Market Incremental Dollar Opportunity, 2026-2036
- Figure 17: Western Europe Market Incremental Dollar Opportunity, 2026-2036
- Figure 18: Eastern Europe Market Incremental Dollar Opportunity, 2026-2036
- Figure 19: East Asia Market Incremental Dollar Opportunity, 2026-2036
- Figure 20: South Asia and Pacific Market Incremental Dollar Opportunity, 2026-2036
- Figure 21: Middle East & Africa Market Incremental Dollar Opportunity, 2026-2036
- Figure 22: North America Market Value Share and BPS Analysis by Country, 2026 and 2036
- Figure 23: North America Market Value Share and BPS Analysis by Source , 2026 and 2036
- Figure 24: North America Market Y-o-Y Growth Comparison by Source , 2026-2036
- Figure 25: North America Market Attractiveness Analysis by Source
- Figure 26: North America Market Value Share and BPS Analysis by Indication, 2026 and 2036
- Figure 27: North America Market Y-o-Y Growth Comparison by Indication, 2026-2036
- Figure 28: North America Market Attractiveness Analysis by Indication
- Figure 29: North America Market Value Share and BPS Analysis by End User, 2026 and 2036
- Figure 30: North America Market Y-o-Y Growth Comparison by End User, 2026-2036
- Figure 31: North America Market Attractiveness Analysis by End User
- Figure 32: Latin America Market Value Share and BPS Analysis by Country, 2026 and 2036
- Figure 33: Latin America Market Value Share and BPS Analysis by Source , 2026 and 2036
- Figure 34: Latin America Market Y-o-Y Growth Comparison by Source , 2026-2036
- Figure 35: Latin America Market Attractiveness Analysis by Source
- Figure 36: Latin America Market Value Share and BPS Analysis by Indication, 2026 and 2036
- Figure 37: Latin America Market Y-o-Y Growth Comparison by Indication, 2026-2036
- Figure 38: Latin America Market Attractiveness Analysis by Indication
- Figure 39: Latin America Market Value Share and BPS Analysis by End User, 2026 and 2036
- Figure 40: Latin America Market Y-o-Y Growth Comparison by End User, 2026-2036
- Figure 41: Latin America Market Attractiveness Analysis by End User
- Figure 42: Western Europe Market Value Share and BPS Analysis by Country, 2026 and 2036
- Figure 43: Western Europe Market Value Share and BPS Analysis by Source , 2026 and 2036
- Figure 44: Western Europe Market Y-o-Y Growth Comparison by Source , 2026-2036
- Figure 45: Western Europe Market Attractiveness Analysis by Source
- Figure 46: Western Europe Market Value Share and BPS Analysis by Indication, 2026 and 2036
- Figure 47: Western Europe Market Y-o-Y Growth Comparison by Indication, 2026-2036
- Figure 48: Western Europe Market Attractiveness Analysis by Indication
- Figure 49: Western Europe Market Value Share and BPS Analysis by End User, 2026 and 2036
- Figure 50: Western Europe Market Y-o-Y Growth Comparison by End User, 2026-2036
- Figure 51: Western Europe Market Attractiveness Analysis by End User
- Figure 52: Eastern Europe Market Value Share and BPS Analysis by Country, 2026 and 2036
- Figure 53: Eastern Europe Market Value Share and BPS Analysis by Source , 2026 and 2036
- Figure 54: Eastern Europe Market Y-o-Y Growth Comparison by Source , 2026-2036
- Figure 55: Eastern Europe Market Attractiveness Analysis by Source
- Figure 56: Eastern Europe Market Value Share and BPS Analysis by Indication, 2026 and 2036
- Figure 57: Eastern Europe Market Y-o-Y Growth Comparison by Indication, 2026-2036
- Figure 58: Eastern Europe Market Attractiveness Analysis by Indication
- Figure 59: Eastern Europe Market Value Share and BPS Analysis by End User, 2026 and 2036
- Figure 60: Eastern Europe Market Y-o-Y Growth Comparison by End User, 2026-2036
- Figure 61: Eastern Europe Market Attractiveness Analysis by End User
- Figure 62: East Asia Market Value Share and BPS Analysis by Country, 2026 and 2036
- Figure 63: East Asia Market Value Share and BPS Analysis by Source , 2026 and 2036
- Figure 64: East Asia Market Y-o-Y Growth Comparison by Source , 2026-2036
- Figure 65: East Asia Market Attractiveness Analysis by Source
- Figure 66: East Asia Market Value Share and BPS Analysis by Indication, 2026 and 2036
- Figure 67: East Asia Market Y-o-Y Growth Comparison by Indication, 2026-2036
- Figure 68: East Asia Market Attractiveness Analysis by Indication
- Figure 69: East Asia Market Value Share and BPS Analysis by End User, 2026 and 2036
- Figure 70: East Asia Market Y-o-Y Growth Comparison by End User, 2026-2036
- Figure 71: East Asia Market Attractiveness Analysis by End User
- Figure 72: South Asia and Pacific Market Value Share and BPS Analysis by Country, 2026 and 2036
- Figure 73: South Asia and Pacific Market Value Share and BPS Analysis by Source , 2026 and 2036
- Figure 74: South Asia and Pacific Market Y-o-Y Growth Comparison by Source , 2026-2036
- Figure 75: South Asia and Pacific Market Attractiveness Analysis by Source
- Figure 76: South Asia and Pacific Market Value Share and BPS Analysis by Indication, 2026 and 2036
- Figure 77: South Asia and Pacific Market Y-o-Y Growth Comparison by Indication, 2026-2036
- Figure 78: South Asia and Pacific Market Attractiveness Analysis by Indication
- Figure 79: South Asia and Pacific Market Value Share and BPS Analysis by End User, 2026 and 2036
- Figure 80: South Asia and Pacific Market Y-o-Y Growth Comparison by End User, 2026-2036
- Figure 81: South Asia and Pacific Market Attractiveness Analysis by End User
- Figure 82: Middle East & Africa Market Value Share and BPS Analysis by Country, 2026 and 2036
- Figure 83: Middle East & Africa Market Value Share and BPS Analysis by Source , 2026 and 2036
- Figure 84: Middle East & Africa Market Y-o-Y Growth Comparison by Source , 2026-2036
- Figure 85: Middle East & Africa Market Attractiveness Analysis by Source
- Figure 86: Middle East & Africa Market Value Share and BPS Analysis by Indication, 2026 and 2036
- Figure 87: Middle East & Africa Market Y-o-Y Growth Comparison by Indication, 2026-2036
- Figure 88: Middle East & Africa Market Attractiveness Analysis by Indication
- Figure 89: Middle East & Africa Market Value Share and BPS Analysis by End User, 2026 and 2036
- Figure 90: Middle East & Africa Market Y-o-Y Growth Comparison by End User, 2026-2036
- Figure 91: Middle East & Africa Market Attractiveness Analysis by End User
- Figure 92: Global Market - Tier Structure Analysis
- Figure 93: Global Market - Company Share Analysis
Full Research Suite comprises of:
Market outlook & trends analysis
Interviews & case studies
Strategic recommendations
Vendor profiles & capabilities analysis
5-year forecasts
8 regions and 60+ country-level data splits
Market segment data splits
12 months of continuous data updates
DELIVERED AS:
PDF EXCEL ONLINE
